Plain-English translation of NCT05405270 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study is testing whether doctors can predict which patients with precancerous cervical changes will respond well to cream, a non-surgical treatment option. Right now, some women do well with this medication while others don't, and researchers want to find biomarkers—measurable signs in your blood or tissue—that can identify ahead of time who will benefit. This could help avoid unnecessary side effects for patients it won't help and preserve surgery for those who truly need it.
Surgery (LLETZ) is the standard treatment for precancerous cervical lesions, but it carries risks like bleeding and can increase the risk of preterm birth in future pregnancies. This medication offers a non-invasive alternative with a 55% success rate, but it causes side effects and treatment takes 16 weeks, so identifying who will respond would help doctors choose the right treatment for each patient.
You likely qualify if…
You likely don't qualify if…
You would apply the topical cream to your cervix for 16 weeks according to the treatment schedule. Researchers would take tissue samples at the beginning and monitor your response to the treatment over time. Some participants will receive the medication directly, while others with CIN 2 may choose to be observed without treatment to see if their lesion goes away naturally—all while researchers collect blood and tissue samples to identify the biomarkers that predict who responds best.
AI-generated summary from trial data · Jun 16, 2026 · Not medical advice
Netherlands